title: Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
abstract: BACKGROUND
  Plasma amyloid beta-peptide (Abeta) can compromise the blood-brain barrier, contributing to cerebrovascular alterations and amyloid angiopathy in Alzheimer's disease (AD). The objectives of this study were to investigate the distribution of lipoprotein-bound plasma-Abeta isoforms.
  
  
  METHODS
  This involved a case-control study of subjects with AD or amnestic mild cognitive impairment (MCI) versus controls. Lipoprotein Abeta distribution was determined in fasted plasma. For assessment of chylomicron homeostasis in the postabsorptive state, subjects were bled 4 h after a low-fat meal. The main outcome measures were plasma lipoprotein Abeta isoform distribution and lipid homeostasis.
  
  
  RESULTS
  We found the majority of plasma Abeta to be associated with triglyceride-rich lipoproteins (TRLs) encompassing chylomicrons, VLDL and IDL. For all lipoprotein groups, Abeta1-40 was the predominant isoform, accounting for approximately 50% of the total. Thereafter, equivalent amounts of the isoforms 1-42, 2-40, 1-38, 1-37 and 1-39 were found. Abeta1-37, Abeta1-38 and Abeta2-40 isoforms were significantly enriched within the TRL fraction of AD/MCI subjects and similar trends were observed for isoforms Abeta1-39, Abeta1-40 and Abeta1-42. Lipoprotein-Abeta was inversely associated with plasma total- and LDL cholesterol. AD/MCI subjects were not dyslipidaemic, however, there was evidence of accumulation of chylomicrons in the postabsorptive state.
  
  
  CONCLUSIONS
  Our data show that Abeta was found to be associated with plasma lipoproteins, especially those enriched with triglyceride. We find that Abeta may be increased in normolipidaemic AD subjects, commensurate with possible disturbances in postprandial lipoprotein homeostasis.
authors.affiliation: Division of Health Sciences, Curtin University of Technology and ATN Centre for Metabolic Health and Fitness. J.Mamo@Curtin.edu.au
authors.forename: J C L
authors.initials: JC
authors.lastname: Mamo
authors.forename: L
authors.initials: L
authors.lastname: Jian
authors.forename: A P
authors.initials: AP
authors.lastname: James
authors.forename: L
authors.initials: L
authors.lastname: Flicker
authors.forename: H
authors.initials: H
authors.lastname: Esselmann
authors.forename: J
authors.initials: J
authors.lastname: Wiltfang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood*; D016229:Amyloid beta-Peptides / Q000097:blood*; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D020033:Protein Isoforms / Q000097:blood
chemical_list: D016229:Amyloid beta-Peptides; D008074:Lipoproteins; D020033:Protein Isoforms